Harris Goldstein Selected Research

Broadly Neutralizing Antibodies

10/2019	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
1/2019	Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.
12/2018	Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
10/2017	Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harris Goldstein Research Topics

Disease

24	Infections 10/2019 - 08/2002
9	HIV Infections (HIV Infection) 10/2019 - 09/2002
7	Acquired Immunodeficiency Syndrome (AIDS) 10/2019 - 10/2004
4	Viremia 12/2020 - 02/2005
3	Neoplasms (Cancer) 01/2019 - 03/2008
2	Disease Progression 10/2017 - 02/2014
2	Coinfection 09/2015 - 02/2014
2	Virus Diseases (Viral Diseases) 12/2009 - 08/2002
2	Encephalitis (Encephalitis, Rasmussen) 01/2006 - 08/2002
2	Dementia (Dementias) 01/2006 - 10/2004
1	Gonorrhea 01/2022
1	Syphilis 01/2022
1	Substance-Related Disorders (Drug Abuse) 01/2016
1	Neurocognitive Disorders (Clerambault Syndrome) 11/2010
1	Persistent Infection 05/2007
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2006

Drug/Important Bio-Agent (IBA)

4	Broadly Neutralizing AntibodiesIBA 10/2019 - 10/2017
4	Cyclin TIBA 01/2016 - 11/2009
3	AntibodiesIBA 12/2018 - 07/2010
3	LuciferasesIBA 01/2016 - 01/2013
2	Tenofovir (Viread)FDA Link 01/2022 - 09/2015
2	EpitopesIBA 10/2019 - 06/2007
2	Proteins (Proteins, Gene)FDA Link 10/2017 - 11/2010
2	Antiviral Agents (Antivirals)IBA 01/2017 - 05/2007
2	nanolucIBA 01/2016 - 09/2015
2	Anti-Infective Agents (Microbicides)IBA 09/2015 - 01/2008
2	RNA (Ribonucleic Acid)IBA 02/2014 - 07/2010
2	Pharmaceutical PreparationsIBA 07/2010 - 10/2004
2	VaccinesIBA 01/2009 - 01/2008
2	Chemokine CCL5IBA 09/2002 - 08/2002
1	Emtricitabine (Emtriva)FDA Link 01/2022
1	Therapeutic UsesIBA 10/2019
1	Chimeric Antigen ReceptorsIBA 01/2019
1	Peptides (Polypeptides)IBA 01/2017
1	4Dm2mIBA 05/2016
1	ProdrugsIBA 09/2015
1	Interleukin-15 (Interleukin 15)IBA 06/2015
1	CD4 Antigens (CD4 Antigen)IBA 02/2015
1	Glycoproteins (Glycoprotein)IBA 02/2015
1	Biological ProductsIBA 02/2014
1	Human immunodeficiency virus 1 p16 proteaseIBA 04/2012
1	Insulin-Like PeptidesIBA 11/2010
1	Immunoglobulin M (IgM)IBA 07/2010
1	HIV AntibodiesIBA 07/2010
1	Immunoglobulin G (IgG)IBA 07/2010
1	Methamphetamine (Desoxyn)FDA LinkGeneric 11/2009
1	LipopolysaccharidesIBA 08/2008
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2008
1	AntigensIBA 03/2008
1	Monoclonal AntibodiesIBA 11/2006
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2006
1	ChemokinesIBA 01/2006
1	Matrix Metalloproteinases (MMPs)IBA 01/2006
1	Tight Junction ProteinsIBA 01/2006
1	Minocycline (Cyclops)FDA LinkGeneric 10/2004
1	CC ChemokinesIBA 09/2002
1	Macrophage Colony-Stimulating FactorIBA 08/2002
1	Macrophage Inflammatory Proteins (Macrophage Inflammatory Protein 1)IBA 08/2002
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 08/2002

Therapy/Procedure

9	Therapeutics 12/2018 - 10/2004
3	Highly Active Antiretroviral Therapy (HAART) 07/2010 - 11/2002
2	Art Therapy 12/2020 - 01/2019
2	Intravenous Injections 01/2016 - 01/2013
2	Transplantation 07/2010 - 07/2010
1	Condoms (Condom) 01/2022
1	Drug Therapy (Chemotherapy) 01/2019
1	Intraperitoneal Injections 07/2010